Relacorilant (Lifyorli) plus nab-paclitaxel delivered a survival benefit in platinum-resistant ovarian cancer, with final overall survival results from the phase 3 ROSELLA study (NCT05257408) presented at the 2026 SGO Annual Meeting. Across 381 patients, median overall survival was 16.0 months with relacorilant plus nab-paclitaxel versus 11.9 months with nab-paclitaxel alone (HR 0.65; 95% CI 0.51–0.83; p=0.0004). The 12- and 18-month survival rates also favored the combination. The benefit was consistent across prespecified subgroups, including prior PARP inhibitor exposure and platinum-free interval length. Final results further reinforced the regimen as a potential new option for this hard-to-treat population. According to the report, the FDA approved the combination in March 2026, and it was added as a preferred option in NCCN guidelines for platinum-resistant ovarian cancer.